In this research, FLT3L and GM-CSF enhanced the anti-tumor effects of the HPV16 E6/E7 vaccine, suggesting that these adjuvants probably reduced the oncogenic effects of E6 and E7. The gene discussed is FLT3LG; the disease is neoplasm.